←
Brett E Fortune MD3,565 posts
Brett E Fortune MD avatar

Brett E Fortune MD

@BrettEFortuneMD

Chief Medical Officer, Miami Transplant Institute, @JacksonHealth, portal HTN, IR/hep, disparities, vascular liver disease/ opinions mine alone

◷ Joined November 2019▧ 103 Photos and videos
AASLD avatar
⟳ Brett E Fortune MD retweeted
AASLD@AASLDtweets·Nov 9

Thank you to everyone who joined us in Denver this week! Our community is what makes The Liver Meeting® what it is, and we’re grateful you were part of it. Save the date for #TLM27 and we'll see you next year! 📍 Philadelphia, PA 🗓️ November 12 - 16, 2027

Post attachment
Saul Karpen avatar
⟳ Brett E Fortune MD retweeted
Saul Karpen@saulkarpen·Nov 10

Great meeting. Nearly 9000 attendees , including 700 APPs, 400 patients, >2700 presentations. Largest exhibitor hall ever ! Fabulous city and convention center. Note that nearly all talks are recorded and there is cc in 15 languages, so can catch what younmissed. Philly in 2027!

Thank you to everyone who joined us in Denver this week! Our community is what makes The Liver Meeting® what it is, and we’re grateful you were part of it. Save the date for #TLM27 and we'll see you next year! 📍 Philadelphia, PA 🗓️ November 12 - 16, 2027

Post attachment
Elliot Tapper avatar
⟳ Brett E Fortune MD retweeted
Elliot Tapper@ebtapper·Nov 8

I am 100% in support of endohepatology 1. I invited the best review on the topic in @HepCommJournal from @allie_schulman and @AhmadBazarbashi journals.lww.com/hepcomm/ful… 2. ❤️what my advanced colleagues can do (endobari, coils, stents) And I am one of the only people

Elliot Tapper avatar
⟳ Brett E Fortune MD retweeted
Elliot Tapper@ebtapper·Oct 22

Follow @JenLaiLiverDoc

Everyone in hepatology and liver transplant is aware of Jennifer C. Lai, MD/MBA’s impact. This week we were privileged to have her as the Sheila Sherlock visiting professor at Michigan Hepatology

Post attachmentPost attachmentPost attachment
Anand V Kulkarni avatar
⟳ Brett E Fortune MD retweeted
Anand V Kulkarni@AnandVKulkarni2·Sep 29

Large multicenter study from India and Singapore. Highlights: TIPS is excellent for AVB (>90% control); decent for Ascites (50% control); For HRS-AKI: survival 52% compared to 73% in no HRS. First study on ACLF type A (APASL)- TFS 33% FIPS and MELD are valid in Asian cohorts @DrMarkMuthiah @DrHuangDQ @RoyAHep @karanbjmc93 @giri_gutnliver @docMPK @BavenoCoop @JimmyLaiCT @Sanchit30497977 @BrettEFortuneMD @ebtapper @JustSagnik @drshalimar @MaiwallRakhi @JasmohanBajaj #liverx #portalhypertension nature.com/articles/s41598-0…

TIPS in higher-risk patients? Multicentric data of 207 patients, 96% remained free of variceal rebleeding, while 51% achieved ascites control. The HRS-AKI and ACLF findings raise important questions Led by @AnandVKulkarni2 @giri_gutnliver @karanbjmc93 nature.com/articles/s41598-0…